Cara tries hard to spin the da­ta, but key PhI­Ib pain study fails and shares slide south

Cara Ther­a­peu­tics tried to spin the da­ta in its fa­vor, but all three dos­es of its lead drug CR845 flopped against a key end­point on pain for os­teoarthri­tis, in­clud­ing the high dose, leav­ing in­ves­ti­ga­tors try­ing to pol­ish up oth­er da­ta sets as an in­di­ca­tion of suc­cess.

The im­por­tant da­ta set that did work out was for pa­tients with os­teoarthri­tis of the hip who com­plet­ed an 8-week course of the high 5 mg dose. But even that was not a home run, with a p-val­ue on pain re­duc­tion of 0.043 com­pared to the place­bo arm. For all OA hip and knee pa­tients who com­plet­ed high-dose ther­a­py there was a failed p-val­ue of 0.111.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER